5-Amino-1MQ
Not a peptide. A small molecule that blocks an enzyme called NNMT. Almost all the data is in mice. Research only. Not a protocol.
What it is
Full name: 5-amino-1-methylquinolinium. A small ring molecule. It blocks NNMT — nicotinamide N-methyltransferase. That enzyme takes nicotinamide (a vitamin B3 piece) and methylates it. When NNMT runs hot in fat tissue, nicotinamide gets spent and NAD+ can fall.
The idea: block NNMT, leave more nicotinamide for NAD+, change how fat cells behave.
Why it is not a peptide
No amino-acid chain. It is a methylquinolinium, not a protein fragment. Shops list it next to BPC-157 because people search both for fat. The chemistry is not the same family.
What researchers studied
Harshini Neelakantan, Stanton McHardy, and colleagues at UTMB / UT published the main paper in Biochemical Pharmacology in 2018. They screened small NNMT blockers that could get through a cell membrane. 5-Amino-1MQ was the one that worked in a dish and in mice.
In mice on a high-fat diet, NNMT blockade cut white fat mass, shrank fat cells, and lowered cholesterol. In cultured fat cells it blocked new fat-cell formation and raised NAD+. Those are mouse and cell results.
Later mouse work from the same line mixed NNMT inhibition with a calorie cut (Dimet-Wiley et al., 2022). Still animals.
There is not a solid, peer-reviewed human outcome trial that says 5-Amino-1MQ does the same thing in people. If a shop tells you otherwise, ask for the paper.
Papers
Neelakantan, Vance, Wetzel et al., 2018 — Membrane-permeable NNMT blockers. High-fat-diet mice lost fat mass. Biochemical Pharmacology. Free at PMC5826726.
Dimet-Wiley et al., 2022 — NNMT inhibition plus a reduced-calorie diet in mice. Scientific Reports.
Yoshino, Yoshino, Imai et al., 2021 — Human NAD+ work is on NMN, not on 5-Amino-1MQ. Linked here so you do not mix the two. Science.
What this is not
Not a peptide. Not a human-proven fat drug. Related to the NAD+ story, but it is not NAD+. This page does not tell you how much to take.